Törnebohm-Roche E, Merup M, Lockner D, Paul C
Department of Internal Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.
Am J Hematol. 1995 Mar;48(3):163-7. doi: 10.1002/ajh.2830480305.
In ten patients with essential thrombocythemia and polycythemia vera with thrombocytosis we have investigated the therapeutic effect of recombinant alpha-2a interferon (Roceron-A) given subcutaneously in a maintenance dosage of 3 million units three times weekly. The aim was to normalize the platelet count (< or = 400 x 10(9)/L). One of the secondary aims was to study platelet activity measured as beta-thromboglobulin (beta-TG) in urine. All but one patient could administer the injections and in all patients a significant reduction in platelet values was seen. The treatment was discontinued in three patients due to side effects of interferon, two because of hair loss (one with irreversible alopecia), and one because of depression. Three patients developed antibodies to alpha-2a interferon and a concomitant rise in the platelet level; in one patient therapy was switched to leukocyte alpha-interferon with an excellent response. The initial levels of beta-TG were elevated in 9/10 patients and were significantly reduced at 6 months in 4/5 patients not developing antibodies. Six patients are still on alpha-interferon therapy with a long-term follow-up of 3-3.5 years. We conclude that alpha-interferon therapy may be an alternative in patients with thrombocytosis and/or complications necessitating treatment.
我们对10例原发性血小板增多症和真性红细胞增多症伴血小板增多的患者进行了研究，皮下注射重组α-2a干扰素（罗扰素-A），维持剂量为每周3次，每次300万单位，目的是使血小板计数恢复正常（≤400×10⁹/L）。次要目的之一是研究以尿β-血小板球蛋白（β-TG）衡量的血小板活性。除1例患者外，所有患者均可自行注射，且所有患者的血小板值均显著降低。3例患者因干扰素的副作用而停药，2例是因为脱发（1例为不可逆性脱发），1例是因为抑郁。3例患者产生了抗α-2a干扰素抗体，同时血小板水平升高；1例患者改用白细胞α-干扰素治疗，效果良好。9/10的患者初始β-TG水平升高，4/5未产生抗体的患者在6个月时β-TG水平显著降低。6例患者仍在接受α-干扰素治疗，长期随访时间为3至3.5年。我们得出结论，对于血小板增多症和/或需要治疗的并发症患者，α-干扰素治疗可能是一种替代治疗方法。
